Jpmorgan Chase & CO Eye Point Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 395,345 shares of EYPT stock, worth $5.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
395,345
Previous 395,444 0.03%
Holding current value
$5.16 Million
Previous $2.95 Million 27.29%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$5.42 - $9.22 $536 - $912
-99 Reduced 0.03%
395,345 $2.14 Million
Q4 2024

Feb 12, 2025
BUY
$7.02 - $12.12 $166,275 - $287,074
23,686 Added 6.37%
395,444 $2.95 Million
Q3 2024

Dec 26, 2024
BUY
$7.58 - $10.54 $2.6 Million - $3.61 Million
342,516 Added 1171.32%
371,758 $2.97 Million
Q3 2024

Nov 08, 2024
BUY
$7.58 - $10.54 $2.6 Million - $3.61 Million
342,516 Added 1171.32%
371,758 $2.97 Million
Q2 2024

Dec 26, 2024
SELL
$8.16 - $22.89 $2.79 Million - $7.84 Million
-342,516 Reduced 92.13%
29,242 $254,000
Q2 2024

Aug 12, 2024
BUY
$8.16 - $22.89 $13,227 - $37,104
1,621 Added 5.87%
29,242 $254,000
Q1 2024

Dec 26, 2024
SELL
$19.93 - $29.71 $6.86 Million - $10.2 Million
-344,137 Reduced 92.57%
27,621 $570,000
Q1 2024

May 10, 2024
BUY
$19.93 - $29.71 $58,913 - $87,822
2,956 Added 11.98%
27,621 $570,000
Q4 2023

Dec 26, 2024
SELL
$5.71 - $24.13 $1.98 Million - $8.38 Million
-347,093 Reduced 93.37%
24,665 $570,000
Q4 2023

Feb 12, 2024
SELL
$5.71 - $24.13 $3.33 Million - $14.1 Million
-583,825 Reduced 95.95%
24,665 $570,000
Q3 2023

Nov 14, 2023
BUY
$7.99 - $15.36 $4.69 Million - $9.02 Million
587,285 Added 2769.56%
608,490 $4.86 Million
Q2 2023

Aug 11, 2023
BUY
$3.03 - $9.0 $1,021 - $3,033
337 Added 1.61%
21,205 $184,000
Q1 2023

May 18, 2023
BUY
$2.28 - $5.04 $45,561 - $100,714
19,983 Added 2257.97%
20,868 $61,000
Q1 2023

May 11, 2023
SELL
$2.28 - $5.04 $33,666 - $74,420
-14,766 Reduced 94.35%
885 $2,000
Q4 2022

Feb 13, 2023
SELL
$2.37 - $7.2 $1,964 - $5,968
-829 Reduced 5.03%
15,651 $55,000
Q3 2022

Nov 14, 2022
BUY
$6.96 - $11.12 $7,189 - $11,486
1,033 Added 6.69%
16,480 $131,000
Q2 2022

Aug 11, 2022
SELL
$7.25 - $12.71 $2,051 - $3,596
-283 Reduced 1.8%
15,447 $122,000
Q1 2022

May 11, 2022
BUY
$8.67 - $14.11 $39,691 - $64,595
4,578 Added 41.05%
15,730 $191,000
Q4 2021

Feb 10, 2022
BUY
$10.18 - $18.4 $30,417 - $54,979
2,988 Added 36.6%
11,152 $136,000
Q3 2021

Nov 12, 2021
BUY
$7.51 - $11.72 $61,311 - $95,682
8,164 New
8,164 $86,000

Others Institutions Holding EYPT

# of Institutions
160
Shares Held
67.1M
Call Options Held
214K
Put Options Held
994K
View Full List

About EyePoint Pharmaceuticals, Inc.

EYPT Quotes by TradingView
  • Ticker EYPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,072,200
  • Market Cap $445M
  • Description
  • EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...
More about EYPT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email